Search

Your search keyword '"Nagafuchi, Hiroko"' showing total 143 results
Start Over Author "Nagafuchi, Hiroko"
143 results on '"Nagafuchi, Hiroko"'

1. Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines

Author

Mouri, Mariko, Imamura, Mitsuru, Suzuki, Shotaro, Kawasaki, Tatsuya, Ishizaki, Yoshiki, Sakurai, Keiichi, Nagafuchi, Hiroko, Matsumura, Norihiro, Uchida, Marina, Ando, Takayasu, Yoshioka, Kohei, Ooka, Seido, Sugihara, Takahiko, Miyoshi, Hiroshi, Mori, Masaaki, Okada, Tomoyuki, Yamaguchi, Masao, Kunishima, Hiroyuki, Kato, Motohiro, and Kawahata, Kimito

Published
2022
Full Text
View/download PDF

4. Establishing clinical remission criteria for giant cell arteritis: Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis

Author

Sugihara, Takahiko, Yoshifuji, Hajime, Uchida, Haruhito A., Maejima, Yasuhiro, Watanabe, Yoshiko, Tanemoto, Kazuo, Umezawa, Natsuka, Manabe, Yusuke, Ishizaki, Jun, Shirai, Tsuyoshi, Nagafuchi, Hiroko, Hasegawa, Hitoshi, Niiro, Hiroaki, Ishii, Tomonori, Nakaoka, Yoshikazu, and Harigai, Masayoshi

Subjects
GIANT cell arteritis, DISEASE remission, TASK forces, SYMPTOMS
Abstract

Objective: To develop a proposal for giant cell arteritis remission criteria in order to implement a treat-to-target algorithm. Methods: A task force consisting of 10 rheumatologists, 3 cardiologists, 1 nephrologist, and 1 cardiac surgeon was established in the Large-vessel Vasculitis Group of the Japanese Research Committee of the Ministry of Health, Labour and Welfare for Intractable Vasculitis to conduct a Delphi survey of remission criteria for giant cell arteritis. The survey was circulated among the members over four reiterations with four face-to-face meetings. Items with a mean score of ≥4 were extracted as items for defining remission criteria. Results: An initial literature review yielded a total of 117 candidate items for disease activity domains and treatment/comorbidity domains of remission criteria, of which 35 were extracted as disease activity domains (systematic symptoms, signs and symptoms of cranial and large-vessel area, inflammatory markers, and imaging findings). For the treatment/comorbidity domain, ≤5 mg/day of prednisolone 1 year after starting glucocorticoids was extracted. The definition of achievement of remission was the disappearance of active disease in the disease activity domain, normalization of inflammatory markers, and ≤5 mg/day of prednisolone. Conclusion: We developed proposals for remission criteria to guide the implementation of a treat-to-target algorithm for giant cell arteritis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Establishing clinical remission criteria for giant cell arteritis: Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis

Author

Sugihara, Takahiko, primary, Yoshifuji, Hajime, additional, Uchida, Haruhito A, additional, Maejima, Yasuhiro, additional, Watanabe, Yoshiko, additional, Tanemoto, Kazuo, additional, Umezawa, Natsuka, additional, Manabe, Yusuke, additional, Ishizaki, Jun, additional, Shirai, Tsuyoshi, additional, Nagafuchi, Hiroko, additional, Hasegawa, Hitoshi, additional, Niiro, Hiroaki, additional, Ishii, Tomonori, additional, Nakaoka, Yoshikazu, additional, and Harigai, Masayoshi, additional

Published
2023
Full Text
View/download PDF

7. Recommendations for the management of the vascular involvement in Behçet's disease by the Japanese National Research Committee for Behçet's disease—secondary publication.

Author

Nagafuchi, Hiroko, Kikuchi, Hirotoshi, Ishibash, Hiroyuki, Maeda, Hideaki, Ogino, Hitoshi, Kirino, Yohei, Sawada, Tetsuji, Saito, Kazuyoshi, Kuwana, Masataka, Hirohata, Shunsei, Ishigatsubo, Yoshiaki, Niimi, Masanori, Okita, Yutaka, Miyata, Tetsuro, Shigematsu, Hiroshi, and Takeno, Mitsuhiro

Subjects
*BEHCET'S disease, *VENOUS thrombosis, *DIFFERENTIAL diagnosis, *TASK forces
Abstract

Objectives: This study aimed to develop clinical guidelines for the management of vascular Behçet's disease (BD) by the Behçet's Disease Research Committee of the Ministry of Health, Labour and Welfare of the Japanese Government. Methods: A task force proposed clinical questions (CQs) concerning vascular BD based on a literature search. After screening, draft recommendations were developed for each CQ and brushed up in three blinded Delphi rounds, leading to the final recommendations. Results: This study provides recommendations for 17 CQs concerning diagnosis and differential diagnoses, assessment of disease activity, and treatment. The guidelines recommend immunosuppressive treatments, for both arterial and venous involvement with active inflammation. Anticoagulation is also recommended for deep vein thrombosis except in high-risk patients. Surgical and endovascular therapies can be optional, particularly in patients with urgent arterial lesions undergoing immunosuppression. In addition, two sets of algorithms for diagnosis and treatment are shown for arterial and venous involvement. Conclusions: These recommendations are expected to serve as useful tools in the daily clinical practice of BD. This content has already been published in Japanese in the Guideline for the Management of Behçet's Disease 2020 and is submitted with permission from both the primary and secondary publishers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Recommendations for the management of the vascular involvement in Behçet’s disease by the Japanese national research committee for Behçet’s disease—secondary publication

Author

Nagafuchi, Hiroko, primary, Kikuchi, Hirotoshi, additional, Ishibash, Hiroyuki, additional, Maeda, Hideaki, additional, Ogino, Hitoshi, additional, Kirino, Yohei, additional, Sawada, Tetsuji, additional, Saito, Kazuyoshi, additional, Kuwana, Masataka, additional, Hirohata, Shunsei, additional, Ishigatsubo, Yoshiaki, additional, Niimi, Masanori, additional, Okita, Yutaka, additional, Miyata, Tetsuro, additional, Shigematsu, Hiroshi, additional, and Takeno, Mitsuhiro, additional

Published
2023
Full Text
View/download PDF

10. CXCL13 as a possible immunological surrogate marker of dermatomyositis: higher levels of CXCL13 in dermatomyositis than polymyositis

Author

Ishizaki, Yoshiki, primary, Sakurai, Keiichi, additional, Kawasaki, Tatsuya, additional, Suzuki, Shotaro, additional, Mouri, Mariko, additional, Endo, Nobuyuki, additional, Ando, Takayasu, additional, Mori, Sho, additional, Toyofuku, Etsushi, additional, Mizushima, Machiko, additional, Tonooka, Kumiko, additional, Yoshioka, Kohei, additional, Kawakami, Misato, additional, Yamazaki, Kazuko, additional, Takakuwa, Yukiko, additional, Nagafuchi, Hiroko, additional, Yamasaki, Yoshioki, additional, Imamura, Mitsuru, additional, Ooka, Seido, additional, Mori, Masaaki, additional, and Kawahata, Kimito, additional

Published
2023
Full Text
View/download PDF

11. Long‐term survival, causes of death, and prognostic factors for mortality in patients with microscopic polyangiitis and those with anti‐neutrophil cytoplasmic antibody‐positive interstitial lung disease: A single‐center retrospective study

Author

Takakuwa, Yukiko, primary, Yamasaki, Yoshioki, additional, Matsushita, Hiromi, additional, Kiyokawa, Tomofumi, additional, Mizushima, Machiko, additional, Tonooka, Kumiko, additional, Nagafuchi, Hiroko, additional, Matsuoka, Shin, additional, Ooka, Seido, additional, and Kawahata, Kimito, additional

Published
2022
Full Text
View/download PDF

12. Nation-wide cohort study of remission induction therapy using rituximab in Japanese patients with antineutrophil cytoplasmic antibody–associated vasculitis: Effectiveness and safety in the first 6 months

Author

Nagasaka, Kenji, primary, Amano, Koichi, additional, Dobashi, Hiroaki, additional, Nagafuchi, Hiroko, additional, Sada, Ken-Ei, additional, Komagata, Yoshinori, additional, Yamamura, Masahiro, additional, Kato, Masaru, additional, Endo, Tomomi, additional, Nakaya, Izaya, additional, Takeuchi, Tsutomu, additional, Murakawa, Yohko, additional, Sugihara, Takahiko, additional, Saito, Masaya, additional, Hayashi, Taichi, additional, Furuta, Shunsuke, additional, Tamura, Naoto, additional, Karasawa, Kazunori, additional, Banno, Shogo, additional, Endo, Shuichiro, additional, Majima, Masako, additional, Kaname, Shinya, additional, Arimura, Yoshiriro, additional, and Harigai, Masayoshi, additional

Published
2022
Full Text
View/download PDF

13. Long‐term survival, causes of death, and prognostic factors for mortality in patients with microscopic polyangiitis and those with anti‐neutrophil cytoplasmic antibody‐positive interstitial lung disease: A single‐center retrospective study

Author

Takakuwa, Yukiko, Yamasaki, Yoshioki, Matsushita, Hiromi, Kiyokawa, Tomofumi, Mizushima, Machiko, Tonooka, Kumiko, Nagafuchi, Hiroko, Matsuoka, Shin, Ooka, Seido, and Kawahata, Kimito

Subjects
INTERSTITIAL lung diseases, MICROSCOPIC polyangiitis, PROGNOSIS, IDIOPATHIC pulmonary fibrosis, CAUSES of death
Abstract

Aim: To elucidate the clinical features, long‐term survival, and prognostic factors for mortality among patients with microscopic polyangiitis (MPA), including those with anti‐neutrophil cytoplasmic antibody‐positive interstitial lung disease (ILD) (ANCA‐ILD), which could be a subset of its variant phenotype. Methods: We retrospectively included 76 consecutive patients between 2006 and 2014, diagnosed with MPA according to the European Medicines Agency algorithm using the Chapel Hill Consensus Conference definitions or ANCA‐ILD. ILD was classified as usual interstitial pneumonia (UIP) or nonspecific interstitial pneumonia pattern using chest computed tomography. Results: The mean (standard deviation) age of the patients (female, 68%) was 69 (12) years. The median (interquartile range) follow‐up period was 68 (33‐95) months. Comorbid ILD and glomerulonephritis were observed in 44 (58%) (68% UIP) and 54 (71%) patients, respectively. Comorbid ILD was associated with low survival (P =.0563). There were 17 (39%) and 5 (16%) deaths in the ILD and non‐ILD groups, respectively (P =.0404). In the ILD group, 6 and 5 of the deaths were attributed to infection and ILD progression, respectively. In the non‐ILD group, 1 and 2 patients expired from subsequently developed ILD and aspiration pneumonia, respectively. Age ≥ 70 years (hazard ratio = 2.78; 95% confidential interval 1.15‐6.70) and UIP (3.95; 1.60‐9.77) were independent risk factors for mortality. Conclusion: Age ≥ 70 years and ILD with a UIP pattern were associated with high mortality, owing to susceptibility to infection and ILD progression. A more effective and less toxic treatment is required for progressive ILD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Serum Levels of Caspase-Cleaved Cytokeratin-18 in Interstitial Lung Disease Associated with Rheumatoid Arthritis, Dermatomyositis, and Polymyositis

Author

Kawasaki, Tatsuya, primary, Imamura, Mitsuru, additional, Nagafuchi, Hiroko, additional, Suzuki, Shotaro, additional, Mouri, Mariko, additional, Ishizaki, Yoshiki, additional, Sakurai, Keiichi, additional, Mizushima, Machiko, additional, Tonooka, Kumiko, additional, Takakuwa, Yukiko, additional, Ooka, Seido, additional, Sugihara, Takahiko, additional, and Kawahata, Kimito, additional

Published
2022
Full Text
View/download PDF

16. Establishing clinical remission criteria and the framework of a treat-to-target algorithm for Takayasu arteritis: Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour and Welfare for intractable vasculitis

Author

Sugihara, Takahiko, primary, Nakaoka, Yoshikazu, additional, Uchida, Haruhito A, additional, Yoshifuji, Hajime, additional, Maejima, Yasuhiro, additional, Watanabe, Yoshiko, additional, Amiya, Eisuke, additional, Tanemoto, Kazuo, additional, Miyata, Tetsuro, additional, Umezawa, Natsuka, additional, Manabe, Yusuke, additional, Ishizaki, Jun, additional, Shirai, Tsuyoshi, additional, Nagafuchi, Hiroko, additional, Hasegawa, Hitoshi, additional, Miyamae, Takako, additional, Niiro, Hiroaki, additional, Ito, Shuichi, additional, Ishii, Tomonori, additional, Isobe, Mitsuaki, additional, and Harigai, Masayoshi, additional

Published
2021
Full Text
View/download PDF

33. Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV

Author

Hanaoka, Hironari, primary, Yamada, Hidehiro, additional, Kiyokawa, Tomofumi, additional, Iida, Harunobu, additional, Suzuki, Takeshi, additional, Yamasaki, Yoshioki, additional, Ooka, Seido, additional, Nagafuchi, Hiroko, additional, Okazaki, Takahiro, additional, Ichikawa, Daisuke, additional, Shirai, Sayuri, additional, Shibagaki, Yugo, additional, Koike, Junki, additional, and Ozaki, Shoichi, additional

Published
2017
Full Text
View/download PDF

34. Recurrent Bilateral Focal Myositis

Author

Nagafuchi, Hiroko, primary, Nakano, Hiromasa, additional, Ooka, Seido, additional, Takakuwa, Yukiko, additional, Yamada, Hidehiro, additional, Tadokoro, Mamoru, additional, Shimojo, Sadatomo, additional, and Ozaki, Shoichi, additional

Published
2016
Full Text
View/download PDF

36. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52

Author

Yamasaki, Yoshioki, primary, Satoh, Minoru, additional, Mizushima, Machiko, additional, Okazaki, Takahiro, additional, Nagafuchi, Hiroko, additional, Ooka, Seido, additional, Shibata, Tomohiko, additional, Nakano, Hiromasa, additional, Ogawa, Hitoshi, additional, Azuma, Kohei, additional, Maeda, Akihiko, additional, Tonooka, Kumiko, additional, Ito, Hiroshi, additional, Takakuwa, Yukiko, additional, Inoue, Makoto, additional, Mitomi, Hirofumi, additional, Kiyokawa, Tomofumi, additional, Tsuchida, Kosei, additional, Matsushita, Hiromi, additional, Mikage, Hidenori, additional, Murakami, Yoshihiko, additional, Chan, Jason Y. F., additional, Ozaki, Shoichi, additional, and Yamada, Hidehiro, additional

Published
2015
Full Text
View/download PDF

40. Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan

Author

Furuta, Shunsuke, primary, Chaudhry, Afzal N., additional, Hamano, Yoshitomo, additional, Fujimoto, Shouichi, additional, Nagafuchi, Hiroko, additional, Makino, Hirofumi, additional, Matsuo, Seiichi, additional, Ozaki, Shoichi, additional, Endo, Tomomi, additional, Muso, Eri, additional, Ito, Chiharu, additional, Kusano, Eiji, additional, Yamagata, Mieko, additional, Ikeda, Kei, additional, Kashiwakuma, Daisuke, additional, Iwamoto, Itsuo, additional, Westman, Kerstin, additional, and Jayne, David, additional

Published
2014
Full Text
View/download PDF

41. Serum level of soluble triggering receptor expressed on myeloid cells-1 as a biomarker of disease activity in relapsing polychondritis

Author

Sato, Tomoo, primary, Yamano, Yoshihisa, additional, Tomaru, Utano, additional, Shimizu, Yukiko, additional, Ando, Hitoshi, additional, Okazaki, Takahiro, additional, Nagafuchi, Hiroko, additional, Shimizu, Jun, additional, Ozaki, Shoichi, additional, Miyazawa, Teruomi, additional, Yudoh, Kazuo, additional, Oka, Hiroshi, additional, and Suzuki, Noboru, additional

Published
2013
Full Text
View/download PDF

44. Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis.

Author

Nagafuchi, Hiroko, Atsumi, Tatsuya, Hatta, Kazuhiro, Muso, Eri, Takeno, Mitsuhiro, Yamada, Hidehiro, and Ozaki, Shoichi

Subjects
*RITUXIMAB, *MICROBODIES, *VASCULITIS, *PREDNISOLONE, *DRUG dosage
Abstract

Objectives. The safety and efficacy of rituximab were examined in a multicenter open-label pilot study in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in Japan. Methods. Patients with refractory AAV were administered a rituximab infusion at a weekly dose of 375 mg/m2 for 4 weeks. All patients also received oral daily prednisolone. The primary outcome was complete remission, which was defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 or 1. Results. The mean age of the 7 patients was 57 (range, 34-71) years. The mean follow-up period after rituximab treatment was 62.9 (range, 4.8-81) months. The mean BVAS at entry was 16.7 (range, 2-34). Complete remission occurred in all cases, except in 1 case in which the patient died, with a significant decline in BVAS from baseline at 12 months after initiation of rituximab. Rituximab reduced granulomatous orbital involvement in a patient with granulomatosis with polyangiitis. Relapse occurred in five patients. Adverse events included de novo hepatitis B in one patient, cancer (hepatocellular carcinoma and prostate cancer) in two patients, and transient visual disturbance, atypical mycobacterial infection, urinary tract infection, sepsis, and cytomegalovirus infection. Two patients died due to recurrent infections and airway obstruction, caused by an AAV lesion. Conclusions. Rituximab had a beneficial effect on refractory AAV in Japanese patients, but several adverse effects occurred during rituximab treatment. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

50. Assessment of the Birmingham vasculitis activity score in patients with MPO-ANCA-associated vasculitis: sub-analysis from a study by the Japanese Study Group for MPO-ANCA-associated vasculitis.

Author

Yumura, Wako, Kobayashi, Shigeto, Suka, Machi, Hayashi, Taichi, Ito, Satoshi, Nagafuchi, Hiroko, Yamada, Hidehiro, and Ozaki, Shoichi

Subjects
COHORT analysis, LONGITUDINAL method, CLINICAL trials, ANTI-antibodies, VASCULITIS, DIAGNOSIS, PATIENTS
Abstract

Objectives. In the study cohort enrolled in a prospective open-label, multicenter trial conducted by the Japanese Study Group for MPO-ANCA-associated vasculitis (JMAAV), we conducted this sub-analysis to establish the validity of the Birminghan vasculitis activity score (BVAS) for Japanese patients with MPO-ANCA-associated vasculitis. Methods. We recorded the BVAS at the time of diagnosis, at 6 weeks after the diagnosis, and at 3, 6, 9, 12, 15 and 18 months after the diagnosis in this study. Results. The most frequently involved organs in the patients were the lungs, kidneys and the nervous system. The kidney (BVAS; new/worse 69.2 %, persistent 40.4 %), general (BVAS; new/worse 67.3 %, persistent 53.8 %), chest (BVAS; new/worse 36.5 %, persistent 46.2 %) and nervous system (BVAS; new/worse 38.5 %, persistent 25.0 %) were the organ systems most frequently involved by the disease at the baseline. The BVAS for new/worse disease decreased immediately after induction therapy, while improvement of the BVAS for persistent disease after therapy differed among the organ systems. Conclusions. BVAS was demonstrated to be a valuable guide for selection of the optimal treatment. Thus, BVAS was also found to be a useful tool in Japanese patients for the assessment of disease activity and degree of organ damage in patients with MPO-ANCA-associated vasculitis. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results